A series of N-substituted cis-tetra- and cis-hexahydrophthalazinone derivatives

have been reported as novel, selective PDE-4 inhibitors with potent anti-inflammatory activity. In order to gain further insights into the structural requirements of novel series of N-substituted cis-tetra and cis-hexahydrophthalazinone derivatives as PDE-4 inhibitors, a three-dimensional quantitative structure activity Microtubule Associat inhibitor relationship (3D-QSAR) was performed using Genetic Function Approximation (GFA). The QSAR model was generated using a training set of 45 molecules and the predictive ability of the resulting each model was assessed using a test set of 9 molecules. The internal and external consistency of final QSAR model was 0.675 and 0.750 respectively. Analysis of results from the present QSAR study indicates that shape and structural descriptors strongly govern the PDE-4 enzyme inhibitory activity. This QSAR study highlights the structural features required for PDE-4 enzyme inhibition and may be useful for design of potent PDE-4 inhibitors.”
“We demonstrate the possibility of doubling the areal density of information in magnetic patterned media by stacking decoupled in-plane and perpendicular-to-plane magnetized layers. Each dot can be set in four magnetostatically equivalent configurations, yielding a storage capability of two-bits per dot. Magnetic force microscopy analyses show that the magnetic signal from the out-of-plane

magnetized layer is dominant right above the dots, whereas, the signal from the in-plane magnetized layers is largest above the spacing Iressa between dots. This results in an optimal use of the storage AZD7762 research buy space and in an increase of the areal density with weak loss in readout signal-to-noise ratio. (C) 2011 American Institute of Physics. [doi: 10.1063/1.3572259]“
“Objective: Maximum seizure

control, preservation of cognition, and prevention of developmental hindrance are major aims of the pharmacological treatment of children and adolescents with epilepsy. Herewith we introduce the junior version of EpiTrack, a 12- to 15-minute screening test for monitoring the cognitive effects of antiepileptic drug treatment in children and adolescents aged 6 to 18.

Methods: The test, which comprises six subtests (Speed, Flexibility, Planning, Response Inhibition, Word Fluency, Working Memory), was administered to 277 children and adolescents aged 6-18 years, 111 of whom were retested after an interval of 3 months. For the first clinical validation, 155 patients (46% idiopathic/benign, 62% seizure free) were evaluated.

Results: Standardization and correction for age resulted in a mean score of 33 +/- 2 points, which was no longer correlated with age (r = 0.005). The retest practice effect was 0.7 +/- 2 points, and the reliability r(tt) = 0.78. Factor analysis indicated one executive factor in controls and patients. In the epilepsy group, 50% of the patients were impaired (controls 14%).